4–6] from the Royal College of Physicians (RCP) in the UK, as well as from Europe and the USA for using radioiodine in the management of hyperthyroidism and of thyroid cancer. The characteristics of ¹³¹I are shown in Table 7.1. As specified by the European Association of Nuclear Medicine (EANM) and the Society of Nuclear Medicine (SNM) [5,6], it is essential that, before any treatment, all thyroid hormones, iodine-containing preparations and supplements and any other medications that could suppress thyroid uptake are discontinued for a sufficient length of time. Almost all thyroid treatments are given orally, as a capsule or as a liquid.

Table 7.1 Properties of the radionuclides used in therapy

Related posts:

descriptors of the radionuclide imaging process Radiation treatment planning: immobilization, localization and verification techniques Principles and practice of radiation treatment planning Oesophagus Dentition

Stay updated, free articles. Join our Telegram channel

Join